Condition-Specific Health
Atavistik Bio Wins FDA Fast Track for ATV-1601 in Rare Vascular Disease
Fast Track status shortens FDA review timelines for serious conditions with unmet need — a designation increasingly rel…
Condition-Specific Health 100 stories
Condition-Specific Health
Life Biosciences' ER-100 Enters Phase 1 for Age-Related Vision Loss
The clinic entry marks a milestone for epigenetic reprogramming as a mechanism in age-related optic neuropathy — a cate…
Condition-Specific Health
NIS4 Biomarker Panel Enters Direct-to-Consumer Lab Market via Labcorp
The move positions non-invasive MASH screening alongside liver-health nutraceuticals at a pivotal moment for the fatty …
Condition-Specific Health
Brainwell Institute, ASO Launch Ontario Dementia Care Task Force
The policy initiative signals growing institutional demand for research-backed brain health solutions — a tailwind for …
Condition-Specific Health
Chronic Pain Research Gap in Women Signals Formulation Opportunity
Pan-Canadian strategy roadmap identifies research and care gaps — opening a lane for evidence-backed nutraceutical and …
Condition-Specific Health
Chronic Pain Gap in Women and Veterans Signals Formulation Opportunity
Pan-Canadian strategy roadmap identifies research, care, and policy gaps — opening space for evidence-backed nutraceuti…
Condition-Specific Health
Gildeuretinol Enters Phase 3 Trial for Stargardt Disease
The deuterium-stabilized vitamin A analog moves into global pivotal testing, raising questions about regulatory classif…
Condition-Specific Health
Neridronate Enters Phase 3 Trial for Rare Pain Condition CRPS-1
With an estimated 65,000 new U.S. cases annually, CRPS-1 represents a significant unmet need that could open upstream i…
Condition-Specific Health
Telitacicept Wins China NMPA Nod for Sjögren's Disease
The NMPA approval marks the first regulatory green light globally for a Sjögren's Disease-specific indication, spotligh…
Condition-Specific Health
Telitacicept Wins China NMPA Nod for IgA Nephropathy
The conditional approval marks a regulatory milestone for dual cytokine inhibition in a kidney disease with limited the…
Condition-Specific Health
Deutetrabenazine Data Show Long-Term TD Symptom Gains
New findings from Psych Congress Elevate underscore neurological symptom management advances, a space adjacent to emerg…
Condition-Specific Health
Teverelix® Phase 2b Filing Targets High-CV-Risk Prostate Cancer Niche
The underserved patient segment represents an estimated $4 billion annual market opportunity, according to the company.